https://www.aramis.admin.ch/Beteiligte/?ProjectID=59986
Towards first-in-class siRNA therapeutics for adrenal targets - Participants
first insirna therapeuticstowardsclassadrenal
https://www.aramis.admin.ch/Grunddaten/?ProjectID=59986&Sprache=de-CH
Towards first-in-class siRNA therapeutics for adrenal targets - Grunddaten
first insirna therapeuticstowardsclassadrenal
https://www.businesswire.com/news/home/20250813527219/en/Sarepta-Therapeutics-Announces-Advancement-of-siRNA-Collaboration-and-Sale-of-Arrowhead-Equity-Investment
Sarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has sold 9,265,312 shares of co...
sarepta therapeuticsannouncesadvancement